Rafarma Pharmaceuticals strengthens its position in Central Asia

Rhea-AI Summary

Rafarma Pharmaceuticals (OTC: RAFA) has expanded its operations in Uzbekistan by planning to build a new pharmaceutical plant in the Tashkent Pharma Park. This facility, adhering to Industry 4.0 standards, aims to produce sterile drugs and fractionated blood plasma elements. The project, expected to generate tens of millions in revenue within 4-5 years, is part of a larger initiative to advance Uzbekistan's pharmaceutical industry. The government is currently preparing regulatory changes to support these developments.

Positive

• Plans to build a new pharmaceutical plant in Uzbekistan, enhancing local production capacity.
• Projected revenue of tens of millions in 4-5 years from the new operations.
• The initiative aligns with government efforts to accelerate the pharmaceutical industry development.

Negative

• None.

Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production.

Over the next three years, the company plans to build a plant there designed according to all Industry 4.0 standards: a flexible industrial base that can easily, quickly and cost-effectively undergo significant modernization and modification depending on production tasks, drugs and required technologies.

The plant will include two production units:

• production of sterile preparations for the market of Uzbekistan and the countries of Central Asia
• production of fractionated blood plasma elements and other products in the form of frozen plasma and blood factors, as well as the development of a network of laboratories for plasma procurement

Rafarma Pharmaceuticals is the initiator of the development of new approaches to the drugs from blood plasma creation in Uzbekistan. The company's project, which became a part of a list of measures to accelerate the development of the pharmaceutical industry in Uzbekistan in 2022-2026, will consist of two stages: the creation of a modern certified laboratories network for plasma collection and then the creation of a plant for its fractionation. In 4-5 years, the business's expected revenue will be tens of millions of dollars.

To date, the country's government is working on legislative changes in the principles of working with blood plasma in the medical sector and is also preparing documents to allow the based on it medicine export. The implementation of the Rafarma Pharmaceuticals project will begin as soon as the necessary regulatory framework creates in the government, which is expected to happen soon.

Uzbekistan ranks first among the Eastern Europe countries in terms of economic growth, and the expected changes will only strengthen the country's influence in the pharmaceutical market.

ABOUT RAFARMA PHARMACEUTICALS:

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.

For more information, please visit https://www.noyarp.com 

FORWARD-LOOKING STATEMENT:

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACTS:
RAFARMA PHARMACEUTICALS 
Info@rafapharm.com
(307) 429-2029

Source: Rafarma Pharmaceuticals, Inc.

FAQ

What are Rafarma Pharmaceuticals' plans in Uzbekistan?

Rafarma Pharmaceuticals plans to build a new pharmaceutical plant in Uzbekistan, producing sterile drugs and blood plasma elements.

What is the expected revenue from Rafarma's project in Uzbekistan?

The expected revenue from Rafarma's operations in Uzbekistan is tens of millions of dollars within 4-5 years.

What are the production focuses of the new Rafarma plant?

The new plant will focus on producing sterile preparations and fractionated blood plasma products.

How does Rafarma's project align with Uzbekistan's pharmaceutical industry?

Rafarma's project is part of legislative changes to bolster the pharmaceutical industry in Uzbekistan from 2022 to 2026.